Hasegawa Masaichi, Ichimura Shoichi, Satomi Kazuhiko
Department of Orthopaedic Surgery, Kyorin University School of Medicine.
Clin Calcium. 2010 Mar;20(3):413-20.
The therapeutic effect of Raloxifene (RLX) on bone turnover markers was investigated in the elderly women with osteoporosis. The mean age of the control group (< 75 years old) was 67.0 years old, similar to a large-scale clinical trial (MORE study) , and that of the elderly group ( > or =years old) was 80.7 years old. The degrees of percentage change from baseline of serum NTX, urine NTX, and BAP in the elderly group were the same as in the control group. The interval of measurement to assess the effect of RLX seems to be appropriate 3 months after treatment in serum and urine NTX, and 6 months in BAP.
在老年骨质疏松女性中研究了雷洛昔芬（RLX）对骨转换标志物的治疗效果。对照组（年龄<75岁）的平均年龄为67.0岁，与大规模临床试验（MORE研究）相似，老年组（年龄≥75岁）的平均年龄为80.7岁。老年组血清NTX、尿NTX和骨碱性磷酸酶（BAP）相对于基线的百分比变化程度与对照组相同。评估RLX效果的测量间隔似乎在治疗后3个月用于血清和尿NTX时是合适的，而对于BAP则是6个月。
